ACADIA Pharmaceuticals Inc (ACAD)

33.63
1.10 3.10
NASDAQ : Health Care
Prev Close 34.71
Open 34.77
Day Low/High 33.61 / 35.22
52 Wk Low/High 16.64 / 50.40
Volume 1.39M
Avg Volume 1.84M
Exchange NASDAQ
Shares Outstanding 121.41M
Market Cap 4.09B
EPS -2.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

What Poker Taught Me About Investing

What Poker Taught Me About Investing

I've learned that emotions have little use at a poker table; they don't in the stock market, either.

What Poker Taught Me About Investing

What Poker Taught Me About Investing

I've learned that emotions have little use at a poker table; they don't in the stock market, either.

Michael J. Yang, Executive Vice President, Chief Commercial Officer (Photo: Business Wire)

Michael J. Yang, Executive Vice President, Chief Commercial Officer (Photo: Business Wire)

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

ACADIA Pharmaceuticals To Present At Needham & Company's 16th Annual Healthcare Conference On April 5, 2017

ACADIA Pharmaceuticals To Present At Needham & Company's 16th Annual Healthcare Conference On April 5, 2017

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

Twitter, Netflix, MetLife: Doug Kass' Views

Twitter, Netflix, MetLife: Doug Kass' Views

Doug Kass shares his thoughts on Twitter and talks about Sears.

4 Smaller Biotech Names Worth Researching

4 Smaller Biotech Names Worth Researching

Here's why to check out Dynavax Technologies as well Lexicon, Supernus and Acadia Pharmaceuticals.

ACADIA Pharmaceuticals Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2016

ACADIA Pharmaceuticals Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2016

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

ACADIA Pharmaceuticals To Present At The Cowen And Company 37th Annual Health Care Conference On March 6, 2017

ACADIA Pharmaceuticals To Present At The Cowen And Company 37th Annual Health Care Conference On March 6, 2017

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals To Announce Fourth Quarter And Full Year 2016 Financial Results On February 28, 2017

ACADIA Pharmaceuticals To Announce Fourth Quarter And Full Year 2016 Financial Results On February 28, 2017

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

Your Burning Biotech Questions Answered

Your Burning Biotech Questions Answered

We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.

Your Burning Biotech Questions Answered

Your Burning Biotech Questions Answered

We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.

Sage Therapeutics Leads Biotech Movers on False Takeout Rumors

Sage Therapeutics Leads Biotech Movers on False Takeout Rumors

In addition to Sage Therapeutics, also moving biotech Friday: Novavax, Cytokinetics and Acadia Pharmaceuticals.

Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta

Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

Welcome to the Small-Cap Biotech Mailbag!

Welcome to the Small-Cap Biotech Mailbag!

We answer recent reader questions about three of the biotech stocks we regularly cover.

Acadia Pops on Takeout Rumors, But Don't Buy on M&A Just Yet

Acadia Pops on Takeout Rumors, But Don't Buy on M&A Just Yet

The company's shares jumped 5% midday Friday on rumors that Astrazeneca could buy Acadia.

The Next Target in Biotech Land

The Next Target in Biotech Land

The Actelion buyout opens the way for other deals.

The Next Target in Biotech Land

The Next Target in Biotech Land

The Actelion buyout opens the way for other deals.

Allergan, Apple, Facebook: Doug Kass' Views

Allergan, Apple, Facebook: Doug Kass' Views

Doug Kass shares his thoughts on buying retail, and discusses why he's favoring the short side in a big way.

Allergan, Citigroup, Apple: Doug Kass' Views

Allergan, Citigroup, Apple: Doug Kass' Views

Doug Kass shares his thoughts on how he had one of his best days in recent memory, and warns you not to look in the rear view mirror.

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

3 Biotechs Screaming 'Takeover Target'

3 Biotechs Screaming 'Takeover Target'

M&A activity should perk up substantially in the small and mid-cap space this year.

Hey, What About the Transports?

They were red today and no one seems to care.

ACADIA Pharmaceuticals To Present At The 35th Annual J.P. Morgan Healthcare Conference On January 10, 2017

ACADIA Pharmaceuticals To Present At The 35th Annual J.P. Morgan Healthcare Conference On January 10, 2017

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

Starbucks, Allergan, Amazon: Doug Kass' Views

Starbucks, Allergan, Amazon: Doug Kass' Views

Doug Kass shares his thoughts on how 2017 will be the year of 'the Dude.'

Acadia Pharmaceuticals Soars After Positive Alzheimer's Disease Study

Acadia Pharmaceuticals Soars After Positive Alzheimer's Disease Study

Shares of Acadia jumped Tuesday after the bio-pharmaceutical company reported positive results for a drug used for Alzehimer's patients.

Acadia Pharma Takes Low Road to Justify Drug Push Into Alzheimer's Psychosis

Acadia Pharma Takes Low Road to Justify Drug Push Into Alzheimer's Psychosis

Acadia Pharmaceuticals uses scant, mediocre clinical data to justify moving Nuplazid into a late-stage clinical trial of Alzheimer's disease psychosis.